title: Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
authors.affiliation: Department of Dermatology, Stanford University, Redwood City, California.
authors.forename: Mina S
authors.initials: MS
authors.lastname: Ally
authors.forename: Ashley
authors.initials: A
authors.lastname: Wysong
authors.forename: Jean Y
authors.initials: JY
authors.lastname: Tang
authors.forename: Sumaira
authors.initials: S
authors.lastname: Aasi
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D011725:Pyridines